Full-Time

Global CAPA Manager

CooperSurgical

CooperSurgical

1,001-5,000 employees

Provides reproductive health products and services

Compensation Overview

$120k - $170k/yr

Trumbull, CT, USA + 1 more

More locations: Livingston, NJ, USA

In Person

On-site in Trumbull, Connecticut or Livingston, New Jersey. Requires 10–20% domestic and/or international travel.

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Veeva
Supply Chain Management
Data Visualization

Get referred to CooperSurgical

See people who can refer or advise you

Requirements
  • Expert knowledge of Corrective and Preventive Action systems, root cause analysis methodologies, effectiveness verification, and quality system investigations.
  • Strong understanding of FDA Quality Management System Regulation, ISO 13485, Medical Device Single Audit Program, EU Medical Device Regulation, and applicable quality system requirements.
  • Experience leading CAPA programs within a global, regulated medical device environment.
  • Demonstrated ability to analyze quality system data and translate findings into actionable improvement plans.
  • Experience supporting regulatory inspections, notified body audits, and remediation activities.
  • Proficiency with electronic Quality Management Systems, including Veeva, TrackWise, MasterControl, or equivalent.
  • Eight to ten or more years of quality experience in a regulated medical device, pharmaceutical, or life sciences industry.
  • Five or more years of direct CAPA, Quality Systems, Compliance, or Quality Engineering experience.
  • Five or more years of leadership experience, including development of technical and professional staff.
  • Experience supporting FDA, MDSAP, notified body, and customer audits.
  • A bachelor's degree in Engineering, Life Sciences, or Chemistry is required.
  • ASQ Certified Quality Auditor, Certified Quality Engineer, or Certified Manager of Quality/Organizational Excellence certification.
Responsibilities
  • Own and maintain the global CAPA Program, including associated procedures, workflows, governance processes, and system requirements.
  • Ensure CAPA processes remain compliant with applicable regulatory requirements and industry standards, including FDA QMSR, ISO 13485, MDSAP, and EU MDR.
  • Establish and maintain standards for CAPA initiation, prioritization, escalation, effectiveness verification, and closure.
  • Serve as the global CAPA process owner and subject matter expert for CAPA-related regulatory expectations and best practices.
  • Ensure inspection-ready documentation and traceability throughout the CAPA lifecycle.
  • Provide oversight of CAPA activities across the organization to ensure timely execution, quality of investigations, and sustainable corrective actions.
  • Review and approve significant CAPAs, investigations, and effectiveness strategies, as required.
  • Monitor CAPA program performance, identify opportunities to improve effectiveness, consistency, and cycle time, and escalate quality system risks and other CAPA key performance indicators.
  • Ensure recurring issues and adverse trends are appropriately assessed and addressed through the CAPA process.
  • Develop and maintain CAPA performance metrics, dashboards, and management review inputs.
  • Analyze program trends to identify systemic quality issues, emerging risks, and opportunities for continuous improvement.
  • Report CAPA program performance, risks, and improvement opportunities to Quality Leadership and senior management.
  • Lead initiatives to improve CAPA process maturity, compliance, efficiency, and user experience.
  • Serve as the CAPA lead during regulatory inspections, notified body audits, and internal audits.
  • Coordinate CAPA-related responses to audit observations, inspection findings, and regulatory commitments.
  • Ensure CAPA processes remain inspection-ready through ongoing monitoring and assessment.
  • Partner with Quality, Regulatory Affairs, Manufacturing, Operations, Research and Development, Supply Chain, and other functions to drive resolution of systemic quality issues.
  • Support strategic quality initiatives and enterprise quality system improvements.
  • Represent the CAPA Program during management reviews and quality governance forums.
  • Perform other duties as assigned.

What CooperSurgical does: CooperSurgical develops and provides products, technologies, and services that support women’s, babies’, and families’ health around the world. How its products work: The company offers a range of reproductive health solutions, including contraception, fertility support, and preventive and therapeutic gynecological care. These products assist clinicians and patients through devices, tests, and therapies designed to aid choice and care in reproductive health. How it differs from competitors: CooperSurgical focuses on a broad set of reproductive health needs—covering contraception, fertility, and gynecologic care—trusted by clinicians worldwide for a wide range of tools and services, which can enable more integrated care compared to providers focused on a narrower segment. Goal: To empower individuals and healthcare professionals to make informed health and life choices and improve care for women, babies, and families globally.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Trumbull, Connecticut

Founded

1990

Get referred to CooperSurgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Paragard's 2024 single-hand inserter improved usability and expanded commercial appeal.
  • The ZyMōt and obp Surgical acquisitions broadened reproductive and surgical offerings.
  • June 2026 sale talks drew multiple bidders, validating CooperSurgical's asset value.

What critics are saying

  • A March 2026 embryo-loss class action attacks trust in CooperSurgical IVF media.
  • Management's 2026 divestiture process signals CooperSurgical can become a sale asset, not a standalone strategy.
  • If IVF customers defect after the recall, CooperSurgical's fertility franchise loses its core growth engine.

What makes CooperSurgical unique

  • CooperSurgical owns Paragard, a rare long-duration nonhormonal contraceptive franchise.
  • Its fertility portfolio spans IVF media, sperm separation, and labor-and-delivery devices.
  • The 2025 Europe direct-sales shift strengthens clinician relationships in France, Italy, Germany, and Spain.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Parental Leave

Fertility Treatment Support

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Company News

CooperSurgical
Feb 12th, 2026
CooperSurgical to Launch Direct Sales Model for Labor and Delivery Portfolio in Key European Markets

CooperSurgical to launch direct sales model for Labor and Delivery portfolio in key european markets. TRUMBULL, CT, December 11, 2025, CooperSurgical(R), a leader in women's healthcare and fertility solutions, today announced a strategic shift to a direct sales model for its premier Labor and Delivery products in France, Italy, Germany, and Spain. This transition will forge a closer relationship with healthcare providers, reinforcing the company's commitment to advancing the standard of care for women and babies. Beginning in the company's fiscal first quarter, healthcare providers and healthcare facilities in these markets will gain the ability to procure products directly from CooperSurgical. The portfolio includes the vacuum-assisted delivery products, Fetal Pillow(TM) cephalic elevation device, the INSORB(R) subcuticular skin stapler, and the Lone Star(R) retractor system. This change from a distributor-led model is designed to streamline the customer's ordering process, facilitate easier access to these critical technologies, and provide direct support from CooperSurgical's dedicated customer care center. By creating a direct channel, CooperSurgical aims to better support the clinical community, ensuring that physicians have the resources and guidance needed to implement these innovative solutions effectively. This initiative is central to the company's mission of delivering technologies that support healthier families. About CooperSurgical CooperSurgical is a leading company dedicated to advancing the health of women, babies, and families. The company's portfolio offers effective solutions that support clinical efficiency from conception to delivery. With a history of innovation in the fertility and women's health field, CooperSurgical has pioneered new technologies and continues to drive progress in the industry. Existing Customers - Order directly from CooperSurgical Previously purchased through a distributor? CooperSurgical, Inc. has simplified the process. Its dedicated sales team can assist with product availability, pricing, ordering, and delivery information specific to your country

PR Newswire
Mar 10th, 2025
2025 Inception Fertility Physician Summit Brings Together Thought Leaders, Researchers, And Clinicians From Across The Company To Celebrate Patient Dedication, Collaborate On Research, And Discuss The Future Of Fertility Care

North America's largest provider of fertility services collaborates, celebrates achievements in fertility care including unparalleled patient services. HOUSTON, March 10, 2025 /PRNewswire/ -- Inception Fertility™ (Inception), North America's largest provider of comprehensive fertility services, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024. The Summit brings together team members, including reproductive specialists and clinical managers, from across Inception's vast network of global fertility clinics, The Prelude Network®, to share best practices and resources that make each clinic a leading fertility provider in their respective markets

FinSMEs
Jan 15th, 2025
Granata Bio Secures $15M Series A+ Funding

Granata Bio Corporation, a biopharma company in Boston, MA, raised $15 million in Series A+ funding. Investors included Gedeon Richter, CooperSurgical, and Amboy Street Ventures. The funds will support the company's pipeline and exploration of new assets in reproductive health. Granata Bio has raised over $30 million to date.

Daily Journal Corporation
Oct 9th, 2024
Toxic embryo culture lawsuits allowed to proceed

Four plaintiffs have filed separate lawsuits against CooperSurgical Inc., accusing the company of selling defective embryo culture which caused embryos to die.

Medical Device Network
Sep 4th, 2024
CooperSurgical introduces single-hand inserter for Paragard IUD

CooperSurgical has introduced a new single-hand inserter for the Paragard copper intrauterine device (IUD).